**Highlights of This Issue** 1693

**SPECIAL FEATURES**

1695  **Molecular Pathways**

- **Metformin: A Therapeutic Opportunity in Breast Cancer**
  Ana M. Gonzalez-Angulo, and Funda Meric-Bernstam

- **Death Receptor Agonists as a Targeted Therapy for Cancer**
  Jeffrey Wiezorek, Pamela Holland, and Jonathan Graves

1709  **CCR Special Focus**

- **Phase I Clinical Trials: Overcoming Barriers**
  Susan E. Bates

- **An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics**
  Patricia M. LoRusso, Scott A. Boerner, and Lesley Seymour

- **Information Needed to Conduct First-in-Human Oncology Trials in the United States: A View from a Former FDA Medical Reviewer**
  Adrian M. Senderowicz

1726  **Approaches to Phase I Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee**

1737  **Performing Phase I Clinical Trials of Anticancer Agents: Perspectives from within the European Union and Japan**

1745  **Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents**

1756  **GCP Data Quality for Early Clinical Development**

1764  **The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee**

1771  **Review**

- **New Developments in Tyrosine Kinase Inhibitor Therapy for Newly Diagnosed Chronic Myeloid Leukemia**
  Philipp le Coutre, Michaela Schwarz, and Theo D. Kim

1781  **Human Cancer Biology**

- **Overexpression of Smoothened Activates the Sonic Hedgehog Signaling Pathway in Pancreatic Cancer–Associated Fibroblasts**
  Kimberly Walter, Noriyuki Omura, Seung-Mo Hong, Margaret Griffith, Audrey Vincent, Michael Borges, and Michael Goggins
CANCER THERAPY: PRECLINICAL

1802  PEA-15 Inhibits Tumorigenesis in an MDA-MB-468 Triple-Negative Breast Cancer Xenograft Model through Increased Cytoplasmic Localization of Activated Extracellular Signal-Regulated Kinase
Chandra Bartholomeusz,
Ana M. Gonzalez-Angulo, Anna Kazansky,
Savitri Krishnamurthy, Ping Liu,
Linda X. H. Yuan, Fumiyuki Yamasaki,
Shuying Liu, Naoki Hayashi,
Dongwei Zhang, Francisco J. Esteva,
Gabriel N. Hortobagyi, and Naoto T. Ueno

1812  Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer
Srinivas Nagaraj, Je-In Youn, Hannah Weber,
Cristina Iclozan, Lily Lu, Matthew J. Cotter,
Colin Meyer, Carlos R. Becerra,
Mayer Fishman, Scott Antonia,
Michael B. Sporn, Karen T. Liby,
Bhupendra Rawal, Ji-Hyun Lee,
and Dmitry I. Gabrilovich

1824  The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemic Cells
Paola Secchiero, Rebecca Volta,
Maria Grazia di Iasio, Elisabetta Mellon,
Mario Tiribelli, and Giorgio Zauli

CANCER THERAPY: CLINICAL

1844  Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
Alan S. Wayne, Robert J. Kreitman,
Harry W. Findley, Glen Lew,
Cynthia Delbrook, Seth M. Steinberg,
Maryalice Stetler-Stevenson,
David J. FitzGerald, and Ira Pastan
Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer
Massimo Cristofanilli, Vicente Valero, Aroop Mangalik, Melanie Royce, Ian Rabinowitz, Francis P. Arena, Joan F. Kroener, Elizabeth Cucio, Claire Watkins, Sarah Bacus, Elsa M. Cora, Elizabeth Anderson, and Patrick J. Magill

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies
Bart Kuenen, Petronella O. Witteveen, Rita Ruijter, Giuseppe Giaccone, Aruna Dontabhaktuni, Floyd Fox, Terry Katz, Hagop Youssefian, Junming Zhu, Eric K. Rowinsky, and Emile E. Voest

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia M. LoRusso, Smitha S. Krishnamurthi, John J. Rinehart, Lisle M. Nabel, Lisa Malburg, Paul B. Chapman, Samuel E. DePrimo, Steven Bentivegna, Keith D. Wilner, Weiwei Tan, and Alejandro D. Ricart

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer

Mesoraline Reduces Mutations in Transforming Growth Factor β Receptor II and Activin Type II Receptor by Improvement of Replication Fidelity in Mononucleotide Repeats
Christoph Campregher, Clemens Honeder, Heekyung Chung, John M. Carethers, and Christoph Gasche

A High Proportion of DNA Variants of BRCA1 and BRCA2 Is Associated with Aberrant Splicing in Breast/Ovarian Cancer Patients
David J. Sanz, Alberto Acedo, Mar Infante, Mercedes Durán, Lucía Pérez-Cabornero, Eva Esteban-Cardenosa, Enrique Lastra, Franco Pagani, Cristina Miner, and Eladio A. Velasco

Correlation of Segmented Metabolic Tumor Volume with Outcome - Letter

Correlation of Segmented Metabolic Tumor Volume with Outcome - Response
Man Ki Chung, Chung-Hwan Baek, and Joon Young Choi
ABOUT THE COVER

Human pancreatic cancer–associated fibroblasts (CAFs) overexpress the Hedgehog receptor SMO. Here, immunohistochemical labeling highlights overexpression of Smo protein in a human primary pancreatic adenocarcinoma. Strong Smo expression is detected in stromal fibroblasts adjacent to pancreatic cancer cells. For details, see the article by Walter and colleagues on page 1781 of this issue.